The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sharlai A.S.

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Gegeliya N.V.

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Druy A.E.

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Konovalov D.M.

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology;
Russian Medical Academy of Continuous Professional Education

«Malignant stroma?» Alternative localization of classical genetic aberrations in neuroblastoma

Authors:

Sharlai A.S., Gegeliya N.V., Druy A.E., Konovalov D.M.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2023;85(4): 47‑53

DOI: 10.17116/patol20238504147

Read: 1202 times

Download PDF (RU)
Contact the author
Table of contents

«MALIGNANT STROMA?» ALTERNATIVE LOCALIZATION OF CLASSICAL GENETIC ABERRATIONS IN NEUROBLASTOMA
«MALIGNANT STROMA?» ALTERNATIVE LOCALIZATION OF CLASSICAL GENETIC ABERRATIONS IN NEUROBLASTOMA

To cite this article:

Sharlai AS, Gegeliya NV, Druy AE, Konovalov DM. «Malignant stroma?» Alternative localization of classical genetic aberrations in neuroblastoma. Russian Journal of Archive of Pathology. 2023;85(4):47‑53. (In Russ.)
https://doi.org/10.17116/patol20238504147

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Neuroblastoma (NB) is a malignant neoplasm originating from the primary cells of the sympathetic nervous system. Patients with NB are risk-stratified using a number of features including age at diagnosis, disease stage, tumor histology and genetic profile (status of NMYC, ALK genes, regions 1p and 11q). The interpretation of the results of genetic studies can become a source of problems because neuroblastoma has a heterogeneous histological pattern. The article describes 2 cases with classical for NB chromosomal aberrations in the stromal component of the tumor.

Keywords:

neuroblastoma
Schwannian stroma
copy number variations
1p
11q

Authors:

Sharlai A.S.

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Gegeliya N.V.

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Druy A.E.

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Konovalov D.M.

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology;
Russian Medical Academy of Continuous Professional Education

Received:

10.01.2023

Accepted:

19.04.2023

Close metadata

References:

  1. Irwin MS, Park JR. Neuroblastoma: paradigm for precision medicine. Pediatr Clin North Am. 2015;62(1):225-256.  https://doi.org/10.1016/j.pcl.2014.09.015
  2. Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA. Neuroblastoma. Nat Rev Dis Primers. 2016;2:16078. https://doi.org/10.1038/nrdp.2016.78
  3. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3(3):203-216.  https://doi.org/10.1038/nrc1014
  4. Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010; 362(23):2202-2211. https://doi.org/10.1056/NEJMra0804577
  5. Malis J. Clinical presentation of neuroblastoma. In: Shimada H, ed. Neuroblastoma. Intech Open; 2013. https://doi.org/10.5772/55921
  6. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83-103.  https://doi.org/10.3322/caac.21219
  7. Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR, eds. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. NIH Pub. No. 99-4649. Bethesda, MD; 1999.
  8. Stiller CA. Epidemiology and genetics of childhood cancer. Oncogene. 2004;23(38):6429-6444. https://doi.org/10.1038/sj.onc.1207717
  9. Kacar A, Paker I, Akcoren Z, Gucer S, Kale G, Orhan D, Talim B, Poyraz A, Uluoglu O, Heper AO, et al. Solid tumors in Turkish children: a multicenter study. World J Pediatr. 2013;9(1):25-31.  https://doi.org/10.1007/s12519-011-0323-3
  10. Ellison L, Janz T. Health at a Glance. Childhood cancer incidence and mortality in Canada. Statistics Canada Catalogue No. 82-624-X. Canada: Minister of Industry; 2015;10.  https://www.statcan.gc.ca/pub/82-624-x/2015001/article/14213-eng.htm/
  11. Baade PD, Youlden DR, Valery PC, Hassall T, Ward L, Green AC, Aitken JF. Trends in incidence of childhood cancer in Australia, 1983-2006. Br J Cancer. 2010;102(3):620-626.  https://doi.org/10.1038/sj.bjc.6605503
  12. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, et al.; INRG Task Force. The international neuroblastoma risk group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27(2):289-297.  https://doi.org/10.1200/JCO.2008.16.6785
  13. Smith V, Foster J. High-risk neuroblastoma treatment review. Children (Basel). 2018;5(9):114.  https://doi.org/10.3390/children5090114
  14. Brady SW, Liu Y, Ma X, Gout AM, Hagiwara K, Zhou X, Wang J, Macias M, Chen X, Easton J, et al. Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations. Nat Commun. 2020;11(1):5183. https://doi.org/10.1038/s41467-020-18987-4
  15. Martinsson T, Eriksson T, Abrahamsson J, Caren H, Hansson M, Kogner P, Kamaraj S, Schönherr C, Weinmar J, Ruuth K, et al. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy. Cancer Res. 2011;71(1):98-105.  https://doi.org/10.1158/0008-5472.CAN-10-2366
  16. Guo C, White PS, Weiss MJ, Hogarty MD, Thompson PM, Stram DO, Gerbing R, Matthay KK, Seeger RC, Brodeur GM, et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene. 1999;18(35):4948-4957. https://doi.org/10.1038/sj.onc.1202887
  17. Plantaz D, Vandesompele J, Van Roy N, Lastowska M, Bown N, Combaret V, Favrot MC, Delattre O, Michon J, Bénard J, et al. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer. 2001;91(5):680-686.  https://doi.org/10.1002/1097-0215(200002)9999:9999<::aid-ijc1114>3.0.co;2-r
  18. Mlakar V, Jurkovic Mlakar S, Lopez G, Maris JM, Ansari M, Gumy-Pause F. 11q deletion in neuroblastoma: a review of biological and clinical implications. Mol Cancer. 2017;16(1):114.  https://doi.org/10.1186/s12943-017-0686-8
  19. Carén H, Kryh H, Nethander M, Sjöberg RM, Träger C, Nilsson S, Abrahamsson J, Kogner P, Martinsson T. High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci USA. 2010;107(9):4323-4328. https://doi.org/10.1073/pnas.0910684107
  20. Hastings RJ, Bown N, Tibiletti MG, Debiec-Rychter M, Vanni R, Espinet B, van Roy N, Roberts P, van den Berg-de-Ruiter E, Bernheim A, et al.; Tumour Best Practice meeting; Eurogentest. Guidelines for cytogenetic investigations in tumours. Eur J Hum Genet. 2016;24(1):6-13.  https://doi.org/10.1038/ejhg.2015.35
  21. Lawce HJ, Sanford JS. Fluorescence in situ hybridization (FISH). In: Arsham MS, Margaret J, Barch MJ, CG(ASCP)CM, Helen J, Lawce HJ, CG(ASCP)CM, eds. The AGT cytogenetics laboratory manual. Ch. 16. 2017;71-831.  https://doi.org/10.1002/9781119061199.ch16
  22. Sauka-Spengler T, Bronner-Fraser M. A gene regulatory network orchestrates neural crest formation. Nat Rev Mol Cell Biol. 2008;9(7):557-568.  https://doi.org/10.1038/nrm2428
  23. Furlan A, Dyachuk V, Kastriti ME, Calvo-Enrique L, Abdo H, Hadjab S, Chontorotzea T, Akkuratova N, Usoskin D, Kamenev D, et al. Multipotent peripheral glial cells generate neuroendocrine cells of the adrenal medulla. Science. 2017;357(6346):eaal3753. https://doi.org/10.1126/science.aal3753
  24. Cohen MA, Zhang S, Sengupta S, Ma H, Bell GW, Horton B, Sharma B, George RE, Spranger S, Jaenisch R. Formation of human neuroblastoma in mouse-human neural crest chimeras. Cell Stem Cell. 2020;26(4):579-592.e6.  https://doi.org/10.1016/j.stem.2020.02.001
  25. Olsen RR, Otero JH, García-López J, Wallace K, Finkelstein D, Rehg JE, Yin Z, Wang YD, Freeman KW. MYCN induces neuroblastoma in primary neural crest cells. Oncogene. 2017;36(35):5075-5082. https://doi.org/10.1038/onc.2017.128
  26. Dong R, Yang R, Zhan Y, Lai HD, Ye CJ, Yao XY, Luo WQ, Cheng XM, Miao JJ, Wang JF, et al. Single-cell characterization of malignant phenotypes and developmental trajectories of adrenal neuroblastoma. Cancer Cell. 2020;38(5):716-733.e6.  https://doi.org/10.1016/j.ccell.2020.08.014
  27. Furlan A, Dyachuk V, Kastriti ME, Calvo-Enrique L, Abdo H, Hadjab S, Chontorotzea T, Akkuratova N, Usoskin D, Kamenev D, et al. Multipotent peripheral glial cells generate neuroendocrine cells of the adrenal medulla. Science. 2017;357(6346):eaal3753. https://doi.org/10.1126/science.aal3753
  28. Hanemaaijer ES, Margaritis T, Sanders K, Bos FL, Candelli T, Al-Saati H, van Noesel MM, Meyer-Wentrup FAG, van de Wetering M, Holstege FCP, Clevers H. Single-cell atlas of developing murine adrenal gland reveals relation of Schwann cell precursor signature to neuroblastoma phenotype. Proc Natl Acad Sci USA. 2021;118(5):e2022350118. https://doi.org/10.1007/s00441-018-2796-z
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.